Jilin Aodong Pharmaceutical Group Co Ltd
Jilin Aodong Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in China. The company provides various drugs, such as oral liquid solutions, injections, capsules, granules, pills, tablets, Chinese herbal medicines, powders, tonic medicines, syrups, and spirits, as well as enzymes, biochemical medicine, and plant chemical medicine. It is also involved in … Read more
Market Cap & Net Worth: Jilin Aodong Pharmaceutical Group Co Ltd (000623)
Jilin Aodong Pharmaceutical Group Co Ltd (SHE:000623) has a market capitalization of $3.02 Billion (CN¥22.17 Billion) as of March 18, 2026. Listed on the SHE stock exchange, this China-based company holds position #4908 globally and #580 in its home market, demonstrating a -0.91% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Jilin Aodong Pharmaceutical Group Co Ltd's stock price CN¥18.54 by its total outstanding shares 1195895387 (1.20 Billion).
Jilin Aodong Pharmaceutical Group Co Ltd Market Cap History: 2015 to 2026
Jilin Aodong Pharmaceutical Group Co Ltd's market capitalization history from 2015 to 2026. Data shows growth from $3.27 Billion to $3.02 Billion (0.58% CAGR).
Index Memberships
Jilin Aodong Pharmaceutical Group Co Ltd is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Shanghai Shenzhen CSI 300
CSI300
|
$1.21 Trillion | 0.17% | #108 of 285 |
Weight: Jilin Aodong Pharmaceutical Group Co Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Jilin Aodong Pharmaceutical Group Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Jilin Aodong Pharmaceutical Group Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.08x
Jilin Aodong Pharmaceutical Group Co Ltd's market cap is 1.08 times its annual revenue
1.01x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
1.81x
Jilin Aodong Pharmaceutical Group Co Ltd's market cap is 1.81 times its annual earnings
10.29x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $3.27 Billion | $2.33 Billion | $2.59 Billion | 1.40x | 1.26x |
| 2016 | $3.31 Billion | $2.74 Billion | $1.67 Billion | 1.21x | 1.99x |
| 2017 | $3.16 Billion | $2.98 Billion | $1.86 Billion | 1.06x | 1.69x |
| 2018 | $2.06 Billion | $3.32 Billion | $935.19 Million | 0.62x | 2.20x |
| 2019 | $2.39 Billion | $3.09 Billion | $1.40 Billion | 0.77x | 1.70x |
| 2020 | $2.41 Billion | $2.25 Billion | $1.71 Billion | 1.07x | 1.41x |
| 2021 | $2.74 Billion | $2.30 Billion | $1.78 Billion | 1.19x | 1.54x |
| 2022 | $2.26 Billion | $2.87 Billion | $1.78 Billion | 0.79x | 1.27x |
| 2023 | $2.33 Billion | $3.45 Billion | $1.46 Billion | 0.68x | 1.60x |
| 2024 | $2.81 Billion | $2.61 Billion | $1.55 Billion | 1.08x | 1.81x |
Competitor Companies of 000623 by Market Capitalization
Companies near Jilin Aodong Pharmaceutical Group Co Ltd in the global market cap rankings as of March 18, 2026.
Key companies related to Jilin Aodong Pharmaceutical Group Co Ltd by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #423 globally with a market cap of $51.97 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #455 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #423 | Zoetis Inc | NYSE:ZTS | $51.97 Billion | $118.15 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.46 |
| #455 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Jilin Aodong Pharmaceutical Group Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Jilin Aodong Pharmaceutical Group Co Ltd's market cap moved from $3.27 Billion to $ 3.02 Billion, with a yearly change of 0.58%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥3.02 Billion | -5.07% |
| 2025 | CN¥3.18 Billion | +13.09% |
| 2024 | CN¥2.81 Billion | +20.76% |
| 2023 | CN¥2.33 Billion | +2.95% |
| 2022 | CN¥2.26 Billion | -17.23% |
| 2021 | CN¥2.74 Billion | +13.64% |
| 2020 | CN¥2.41 Billion | +0.72% |
| 2019 | CN¥2.39 Billion | +15.96% |
| 2018 | CN¥2.06 Billion | -34.73% |
| 2017 | CN¥3.16 Billion | -4.63% |
| 2016 | CN¥3.31 Billion | +1.36% |
| 2015 | CN¥3.27 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Jilin Aodong Pharmaceutical Group Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.02 Billion USD |
| MoneyControl | $3.02 Billion USD |
| MarketWatch | $3.02 Billion USD |
| marketcap.company | $3.02 Billion USD |
| Reuters | $3.02 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.